Aptose Biosciences (NASDAQ:APTO) stock is on the move Friday after announcing details for a public offering of the clinical-stage biotechnology company’s shares.
Aptose Biosciences is selling 4.91 million shares of its common stock at a price of $1.71 per share. That has it expecting gross proceeds of $8.4 million from the stock offering.
To go along with this, each share of APTO stock sold in the offering comes with one warrant. These warrants are for the purchase of another share of the company’s stock. The exercise price of them matches the sale price of the shares.
In addition to this, the underwriters of the offering have a 30-day option to acquire another 736,842 shares and warrants of APTO stock. Newbridge Securities is the sole book-running manager of the offering.
APTO Stock Private Placement
Aptose Biosciences also announced a private placement alongside its public offering. The company is selling $4 million worth of its common stock to Hanmi Pharmaceutical. That will give it a 19.97% stake in the company.
Hanmi Pharmaceutical is also paying more for those shares than the price in the public offering. It will purchase each share of APTO stock for $1.90 each. This is helping soften the blow of the discounted price in the public stock offering.
APTO stock is down 1.6% as of Friday morning.
Investors looking for more of the most recent stock market stories will want to stick around!
We’re offering up coverage of all the latest stock market news for Friday! A few examples include what’s happening with shares of Ekso Bionics (NASDAQ:EKSO) and Aclarion (NASDAQ:ACON) stock today, as well as the biggest pre-market stock movers this morning. All of this news is ready to go at the following links!
More Friday Stock Market News
- Why Is Ekso Bionics (EKSO) Stock Up 5% Today?
- Why Is Aclarion (ACON) Stock Up 109% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
